Citation for published version (APA):
Autoimmune pathology has been suggested as an aetiology for some cases of schizophrenia, with increasing evidence implicating N-methyl-D-aspartate receptor (NMDA-R) autoantibodies.\(^1,2\) NMDA-R hypofunction is postulated as a mechanism underlying the development of schizophrenia.\(^3\) Support for this theory comes from cases of NMDA-R encephalitis, which often presents with symptoms of psychosis before rapidly progressing to seizures, movement disorders, impaired consciousness, autonomic instability and respiratory distress.\(^4\) Previous studies have identified serum NMDA-R autoantibodies in 4.3% of a prospective cohort of patients with first-episode psychosis\(^2\) and 9.9% of acutely ill patients with schizophrenia – either in the first episode or experiencing an acute exacerbation of their illness.\(^1\) These studies indicate that 4–10% of patients in the first episode or acute phases of schizophrenia have NMDA-R autoantibodies. A recent study found that 10.5% of participants were seropositive for NMDA-R antibodies with no difference in seroprevalence between patients with schizophrenia and healthy controls.\(^5\) The same authors demonstrated in animal studies that NMDA-R autoantibodies have behavioural effects only in rodents with a compromised blood–brain barrier. This led them to hypothesise that it is a disruption of blood–brain barrier integrity in schizophrenia that leads to NMDA-R autoantibodies being able to enter the brain to a greater extent than in healthy controls. About one in three patients with schizophrenia has a treatment-refractory condition – defined by the National Institute of Health and Care Excellence (NICE) as persistent psychotic symptoms associated with distress and functional impairment that have not responded to at least two adequate trials of different antipsychotics. An adequate treatment trial was defined as treatment at a dose within the British National Formulary (www.bnf.org) therapeutic range for at least 6 weeks, with good adherence indicated by receipt of a long-acting injection as prescribed, or, for oral antipsychotics, a serum antipsychotic level within the therapeutic range.\(^6\) The primary outcome measure was seropositivity for NMDA-R antibodies. A standardised cell-based assay was used for the detection of serum immunoglobulin (IgG) antibodies directed against the NR1 and NR2b subunits of the NMDA-R.\(^10\) This was performed by the Department of Clinical Neurology, John Radcliffe Hospital, University of Oxford. Study approval was granted by the Psychosis Clinical Academic Group Audit committee at South London and Maudsley NHS Foundation Trust, London UK. Every effort has been made to preserve the anonymity of the patients in the case reports.

### Methods

The sample consisted of 43 referrals (January 2011 to August 2013) to the services for treatment-refractory psychosis at South London and Maudsley NHS Foundation Trust. Routine socio-demographic and clinical data were collected as part of the assessment. These related to gender, age, ethnicity, diagnosis, duration of illness, response to treatment and NMDA-R autoantibody status. Inclusion criteria were meeting the ICD-10 criteria for schizophrenia (F20) or schizoaffective disorder (F25),\(^8\) and meeting the following criterion for treatment resistance:\(^7\) persistent psychotic symptoms associated with distress and functional impairment that have not responded to at least two adequate trials of different antipsychotics. An adequate treatment trial was defined as treatment at a dose within the British National Formulary (www.bnf.org) therapeutic range for at least 6 weeks, with good adherence indicated by receipt of a long-acting injection as prescribed, or, for oral antipsychotics, a serum antipsychotic level within the therapeutic range.

The sample comprised 43 patients (32 males and 11 females; mean age 40.3 years (s.d. = 11.1, range 20–69); schizophrenia, n = 36; schizoaffective disorder, n = 7). The mean duration of illness was 15.7 years (s.d. = 9.4, range 2–37) and all met criteria for refractory illness.\(^8\) Three patients were seropositive for IgG antibodies directed against NMDA-R – giving a point prevalence of 7.0%. All had low serum antibody titres (1:50, 1:50, 1:100). All three had normal MRI brain imaging and none had a history of delirium, neurological symptoms or signs, seizures or carcinoma. None of the patients had an electroencephalogram or cerebrospinal fluid (CSF) analysis.

The first patient was a 30-year-old White man, with a 10-year history of treatment-refractory paranoid schizophrenia, with a
serum NMDA-R antibody titre of 1:50. The unremitting psychotic illness was characterised by grandiose and religious delusions, perceptual disturbances and conceptual disorganisation, as well as negative symptoms such as poor self-care and social withdrawal. His Brief Psychiatric Rating Scale-18 (BPRS-18) score at the time of serum antibody testing was 63. The positive antibody result was identified concurrent to ongoing clozapine treatment. He displayed a good clinical response to maintenance clozapine therapy – reflected in a reduction in the BPRS-18 score to 30 after 6 months of treatment. A repeat NMDA-R antibody test at 6 months after the initial assay was negative.

The second patient was a 31-year-old Black British man with a 3-year history of treatment-refractory paranoid schizophrenia. He had a serum NMDA-R antibody titre of 1:100. His initial presentation was marked by disorganisation of thought processes, delusions of reference and perceptual disturbances – including visual and command auditory hallucinations. The illness course was characterised by persistent positive psychotic symptoms. He had a BPRS-18 score of 52 on initial assessment, when he was treated with paliperidone palmitate. A second serum titre taken 5 weeks after his first positive result was 1:50 indicating a reduction in antibody levels without any noticeable change in clinical presentation. He showed a good clinical response to clozapine, demonstrated in a reduced BPRS-18 score of 31 after 5 months of clozapine treatment.

The third patient was a 41-year-old White woman. She had a serum NMDA-R antibody titre of 1:50. She had a diagnosis of treatment-refractory paranoid schizophrenia, with an illness duration of 16 years. Her illness was characterised by unremitting olfactory and tactile hallucinations. She had a BPRS-18 score of 71. She had a history of head injury with loss of consciousness but without sequelae. At the time of the antibody assay she was treated with quetiapine. She declined a change to her medication and her psychosis persists.

Discussion

This study found that 3 out of 43 patients (7.0%) with chronic refractory psychosis were positive for NMDA-R autoantibodies. These results do not support our hypothesis that NMDA-R autoantibodies specifically underlie treatment-refractory schizophrenia, although research in larger samples is needed. Given recent evidence suggesting that seropositivity occurs in the acute phase of illness for those with chronic psychoses,1 it is possible that some of the seronegative patients with chronic refractory psychosis were seropositive for NMDA-R autoantibodies earlier in their illness. It is also possible that antipsychotic treatment may have decreased antibody titre. Thus, we cannot exclude the possibility that the patients had NMDA-R autoantibodies earlier in their illness, and that the effects of this persisted after NMDA-R antibody production had ceased. In all three of the participants who were seropositive, the antibody titres were low. The clinical significance of low titres in patients presenting with refractory psychosis and without the characteristic clinical syndrome remains to be determined. Although CSF and, to a lesser extent, serum antibody titres have been shown to be related to illness severity in NMDA-R encephalitis,12 a similar correlation has not yet been demonstrated in any stage of psychosis. In this study only serum samples were tested for the presence of NMDA-R antibodies, and it may be that the sensitivity of antibody testing could have been increased through the use of CSF.12 This assertion remains controversial,10 and has not been assessed in a population of individuals with treatment-refractory schizophrenia.

Limitations of our study were the relatively small sample size, the lack of a control group and the preponderance of men in our sample. The latter may be important, given evidence from studies of NMDA-R encephalitis indicating that women are more likely to be seropositive.5 Nevertheless, the excess of men in our sample is typical of refractory schizophrenia.6

Our study findings do not support the hypothesis that NMDA-R autoantibodies are a common aetiology in refractory psychotic illnesses, although we cannot exclude a role for them in the pathoetiology of a subgroup of individuals. At present, there is no evidence that this is a useful routine investigation in refractory psychosis. However, further investigation is needed, given that there is evidence that some people with psychosis respond to immunomodulatory therapy.16

Acknowledgements

We thank Professor A. Vincent for assistance in analysis and interpretation of the results.

References

Prevalence of serum N-methyl-d-aspartate receptor autoantibodies in refractory psychosis
Katherine Beck, John Lally, Sukhwinder S. Shergill, Michael A. P. Bloomfield, James H. MacCabe, Fiona Gaughran and Oliver D. Howes
BJP 2015, 206:164-165.
Access the most recent version at DOI: 10.1192/bjp.bp.113.142216

References
This article cites 11 articles, 3 of which you can access for free at:
http://bjp.rcpsych.org/content/206/2/164#BIBL

Reprints/permissions
To obtain reprints or permission to reproduce material from this paper, please write to permissions@rcpsych.ac.uk

You can respond to this article at
/letters/submit/bjprcpsych;206/2/164

Downloaded from
http://bjp.rcpsych.org/ on May 6, 2015
Published by The Royal College of Psychiatrists